Home›The Library›Daptomycin
Daptomycin
Daptomycin (Cubicin) is a real, FDA-approved cyclic lipopeptide antibiotic — the first entry in a new category for this site, peptide-based antibiotics — with a genuinely interesting limitation: it's inactivated by lung surfactant, so it cannot be used to treat pneumonia no matter how susceptible the bacteria are.
On this page
In brief
Should you care? Relevant only in the context of serious gram-positive bacterial infections — a hospital-only antibiotic with no wellness angle, but a genuinely interesting mechanism.The short version
- A calcium-dependent, membrane-disrupting cyclic lipopeptide — a mechanism unlike standard cell-wall or protein-synthesis antibiotics.
- Approved September 2003 for serious skin infections; expanded in 2006 to bacteremia and endocarditis.
- Cannot treat pneumonia — lung surfactant inactivates it, a real and clinically important limitation regardless of how susceptible the bacteria are.
A membrane-disrupting mechanism
Daptomycin is a cyclic lipopeptide antibiotic, first-in-class for its mechanism: in the presence of calcium, it inserts into the gram-positive bacterial cell membrane, oligomerizes, and causes rapid depolarization and potassium efflux, killing the cell without directly attacking the cell wall itself. That distinguishes it from most other antibiotics on this site's eventual roster, which work by blocking cell-wall synthesis or protein synthesis instead.
The approval and pivotal trials
The FDA approved daptomycin (as Cubicin) on 12 September 2003 for complicated skin and skin-structure infections, based on trials including Arbeit et al. (Clin Infect Dis 2004, PMID 15227611). The label was expanded in 2006 to cover Staphylococcus aureus bacteremia and right-sided endocarditis, based on Fowler et al. (N Engl J Med 2006, PMID 16914701): 246 patients, daptomycin found non-inferior to standard therapy (gentamicin plus an antistaphylococcal penicillin or vancomycin) — treatment success in 44.2% of the daptomycin group versus 41.7% on standard therapy, a modest, non-inferior result rather than a clear win, with a higher rate of emergent non-susceptibility to daptomycin during treatment in that arm worth being precise about rather than glossing over.
Why it can't treat pneumonia
A specific, well-documented limitation: daptomycin is inactivated by pulmonary surfactant, the lipid-protein mixture that coats healthy lung tissue (Silverman et al., J Infect Dis 2005). This isn't a susceptibility problem with the bacteria — daptomycin can kill the same organism perfectly well in blood or skin tissue — it's that surfactant itself neutralizes the drug in the lung environment specifically, so it failed to meet non-inferiority in a clinical trial for community-acquired pneumonia and has never been indicated for that use.
Safety
The labeled risk that matters most in practice is myopathy: daptomycin can cause muscle pain/weakness with significant CPK elevation, up to and including rhabdomyolysis. The label directs weekly CPK monitoring and discontinuation at defined thresholds, and prescribers are cautioned about combining it with statins given the overlapping muscle-toxicity risk.
References
- Fowler VG Jr, Boucher HW, Corey GR, et al., "Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus," N Engl J Med 2006;355(7):653-665, PMID 16914701, DOI: 10.1056/NEJMoa053783.
- Silverman JA, Mortin LI, VanPraagh ADG, Li T, Alder J, "Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact," J Infect Dis 2005;191(12):2149-2152, DOI: 10.1086/430352.
- Arbeit RD, Maki D, Tally FP, et al., "The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections," Clin Infect Dis 2004;38(12):1673-1681, PMID 15227611.
- FDA approval history for Cubicin (daptomycin), 12 September 2003.